GLP‑1 Microdosing: What It Is and What the Evidence Says

There is no official definition, but the term usually describes using a fraction of a standard dose or stretching the interval between doses. A 2026 commentary in Expert Opinion on Pharmacotherapy describes microdosing as typically using 25% to 50% of the manufacturer's recommended starting dose, or extended dosing intervals.1

The same authors note that the practice spread during the GLP-1 shortages, through patient communities, telemedicine weight-loss programs and clinician anecdotes.1 A separate 2026 report for nurse practitioners links its growth to cost barriers, gastrointestinal side effects and the use of products from unregulated sources after the shortages ended.2

Microdosing is different from the slow start every label already builds in. Both Zepbound and Wegovy begin at a low dose specifically to reduce gastrointestinal side effects, then step up.4,6

Microdosing tirzepatide usually means taking less than Zepbound's 2.5 mg starting dose, or staying long-term at a dose below the approved maintenance range.1,4

The Zepbound label is specific on both points. The starting dose is 2.5 mg once weekly for four weeks, and the label says the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose.4 The approved maintenance doses are 5 mg, 10 mg or 15 mg once weekly.4 Mounjaro's label likewise says the 2.5 mg starting dose is not intended for glycemic control.5

So any regimen below 2.5 mg, or a long-term plan at 2.5 mg, is outside the label. That does not make it illegal for a clinician to prescribe — off-label prescribing is common in medicine — but it does mean the regimen has not been tested for safety and effectiveness the way the labeled doses have.

For comparison, these are the schedules the FDA approved for weight management.

Sources: the Zepbound and Wegovy prescribing information.4,6 Wegovy's maximum of 7.2 mg is for adults who have tolerated 2.4 mg for at least four weeks and need further weight reduction.6 Everything below the starting dose, or between labeled steps, is outside these schedules.

Very little, and none of it from large randomized trials of sub-starting doses.

• Reviews. The 2026 Expert Opinion commentary concludes that early reports suggest possible benefits such as less nausea and better adherence with modest weight loss, but that high-quality clinical evidence remains limited.1
• One low-dose cohort. A non-randomised 2026 study of 112 Japanese adults without diabetes compared staying on tirzepatide 2.5 mg with moving to 5 mg, alongside diet and exercise counselling. At 6 months, average weight loss was 15.3% and 16.1% respectively, and adverse events were less frequent at the lower dose (35% vs 50%).3 This was not a randomized trial, it lasted 6 months, the population had a mean BMI of 30.8, and 2.5 mg is still the full labeled starting dose — not a microdose.3
• The dose-response in trials. In SURMOUNT-1, weight loss at 72 weeks rose with dose: 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg.7 The trial did not test doses below 5 mg as maintenance.7

Large trials do show what happens when treatment stops altogether. In STEP 4, people switched from semaglutide 2.4 mg to placebo regained an average of 6.9% of body weight over 48 weeks, while those who continued lost a further 7.9%.8 In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% over 52 weeks, while those who continued lost a further 5.5%.9 Those trials compared full doses with placebo, so they do not tell us whether a reduced dose would hold weight off.8,9

Zepbound is not approved for microdosing, and the label gives no instructions for doses below 2.5 mg or for spacing doses beyond weekly.4 Anyone considering a lower dose should do it with a prescriber, not by improvising.

What the label does say about tolerability:

• Escalation pace. Doses go up in 2.5 mg steps, each after at least four weeks on the current dose.4
• Lower maintenance. If a maintenance dose is not tolerated, the label says to consider a lower maintenance dose — within the approved 5 mg to 15 mg range.4
• Missed doses. A missed dose can be taken within four days; after that it should be skipped.4

Wegovy's label offers a similar lever: if a dose is not tolerated during escalation, it suggests considering a four-week delay before the next increase, and maintenance can be 1.7 mg or 2.4 mg.6 Our Zepbound dosage guide covers the full schedule.

The 2026 Expert Opinion commentary describes techniques people use, such as "click counting" with multidose pens, and flags concerns about non-standard dose measurement and dosing accuracy.1 The FDA has separately received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide.10

Much microdosing relies on compounded vials, which adds a second layer of risk. The nurse-practitioner report highlights pen manipulation, compounded vials and medication sharing as specific safety concerns.2

The FDA advises discarding multi-dose compounded vials 28 days after first use.10 Since the shortages ended, compounded copies of approved GLP-1 drugs may only be made under narrow conditions, for an individual patient, unless a prescriber documents a significant clinical difference.11 Our guides to compounded tirzepatide and compounded semaglutide explain the current rules.

No provider can offer microdosing as an FDA-approved regimen, because none exists. When comparing companies that advertise it, the FDA's guidance on compounded drug marketing is a useful filter:12

• The company should not describe a compounded drug as FDA-approved or as a generic version of an approved drug.
• It should name the pharmacy that actually compounds the product.
• It should not claim compounded products produce the same results as approved drugs.

A provider that prescribes an approved drug at a reduced dose should explain that the regimen is off-label, how the dose will be measured, and how it will be monitored. Our ranking of the best GLP-1 providers lists vetted options.

Is GLP-1 microdosing FDA-approved? No. The approved regimens are the dose schedules in each label, such as 5 mg to 15 mg weekly for Zepbound maintenance.4

Does microdosing GLP-1 work? There is not enough evidence to say. A 2026 review describes high-quality evidence as essentially absent.1

What is the lowest approved dose of Zepbound? 2.5 mg weekly, as a starting dose only; the lowest approved maintenance dose is 5 mg.4

Is microdosing safer? Lower doses may cause fewer gastrointestinal side effects, but non-standard measuring raises the risk of dosing errors, especially with compounded vials.1,10

Can I microdose to keep weight off after stopping? That has not been tested in large trials. Withdrawal trials show substantial regain after stopping full-dose treatment.8,9

If side effects or cost are what is pushing you toward microdosing, a prescriber-led plan is the place to start. The tirzepatide online guide sets out brand-name routes with clear pricing, and our ranking of the best compounded tirzepatide providers covers compounded options and how they source.

This article is for information only and is not medical advice. Microdosing is off-label. Do not change your dose without talking to the clinician who prescribes it.